Voyager Therapeutics, INC Schedule 13G passive stakes

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 3,436,000 shares, representing 5.58% of Voyager Therapeutics, Inc.'s common stock, as of June 30, 2026.

Several entities, including Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, have jointly filed a Schedule 13G regarding their beneficial ownership of Voyager Therapeutics, Inc. common stock.

EcoR1 Capital, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. have filed an amended Schedule 13G, reporting zero beneficial ownership in Voyager Therapeutics, Inc. common stock.

Armistice Capital, LLC and Steven Boyd report beneficial ownership of 5.87% of Voyager Therapeutics, Inc. common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Voyager Therapeutics Inc. following an internal realignment.

Millennium Management LLC and affiliated entities have reported a passive beneficial ownership of 6.1% in Voyager Therapeutics, Inc. common stock.

Armistice Capital, LLC and Steven Boyd reported a 7.57% beneficial ownership stake in Voyager Therapeutics, Inc. as of September 30, 2025.

EcoR1 Capital, LLC and its affiliates reported an amended beneficial ownership of 6.8% in Voyager Therapeutics, Inc., totaling 4,003,636 shares, including warrants.

Armistice Capital, LLC and Steven Boyd have disclosed a beneficial ownership of 8.65% in Voyager Therapeutics, Inc., totaling 4,800,000 shares of common stock.

Armistice Capital, LLC and Steven Boyd have jointly disclosed a beneficial ownership of 9.85% in Voyager Therapeutics, Inc., holding 5,436,000 shares of common stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.4% beneficial ownership stake in Voyager Therapeutics, Inc. as of March 31, 2025.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 9.88% of Voyager Therapeutics, Inc.'s common stock as of December 31, 2024.